81 results about "Aspirin" patented technology

The invention discloses a glucose responsive composite material as well as a preparation method and application thereof. The composite material sequentially comprises porous metal, a polydopamine layer and a mesoporous silicon dioxide coating from inside to outside, the porous metal is coated with the polydopamine layer, the polydopamine layer is coated with the mesoporous silicon dioxide coating, and preparation raw materials of the mesoporous silicon dioxide coating comprise aminated mesoporous silicon dioxide, aspirin, 4-carboxyphenylboronic acid and sodium alginate. The composite material disclosed by the invention has blood sugar concentration dual-mode response capability, aspirin is suddenly released in a hyperglycemia environment, up-regulation expression of anti-inflammatory factors is remarkably promoted, and an anti-inflammatory effect is dominated; in a normal blood glucose environment, aspirin is slowly released, and the expression of osteogenic factors is remarkably up-regulated, so that osteogenic differentiation is promoted as a leading effect; the dual-mode response realizes accurate regulation and control of ASP dosage, organically combines bone formation promotion and anti-inflammatory functions, and provides a brand new solution for patients with bone defects, especially patients with bone defects caused by diabetes mellitus.

The invention discloses an aspirin enteric-coated micro-tablet capsule and a preparation method thereof. The micro-tablet core auxiliary materials of the enteric-coated micro-tablet capsule comprise an excipient, a disintegrating agent, a stabilizer, a flow aid and a lubricant. Tartaric acid is adopted as a stabilizer of aspirin, gel silicon dioxide is adopted as a flow aid, a moisture absorption agent and a swelling agent, and a direct powder tabletting method is adopted to prepare a micro-tablet core; the invention provides the aspirin enteric-coated micro-tablet capsule which is good in powder flowability, stable and easy to control in process, good in stability, uniform in dissolution and release characteristics, stable in blood concentration and high in bioavailability.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an aspirin enteric-coated composition and a preparation method thereof.The composition comprises centrifugally granulated particles, an isolating layer and an enteric-coated layer, and the isolating layer and the enteric-coated layer sequentially wrap the centrifugally granulated particles; the centrifugally granulated particles comprise the following components: 19-22% of aspirin, 44-53% of a filler, 3-4% of an adhesive and 0.3-0.5% of a stabilizer, the isolating layer comprises the following components: 3-5% of a film-forming material and 3-5% of an anti-sticking agent, and the enteric-coated layer comprises the following components: 14-19% of an enteric-coated material, 0.4-0.6% of a plasticizer and 2-3% of an anti-sticking agent. According to the invention, aspirin is prepared into enteric-coated particles, and other flavoring auxiliary materials are selectively added, so that the oral preparation for children, which is good in palatability, relatively easy to swallow, easy to divide dosage, more accurate and more convenient, is obtained.

The invention relates to a pharmaceutical composition for treating uterine adhesion and application thereof. The kidney reinforcing and miscarriage preventing pills are used for improving endometrial blood perfusion and increasing the endometrial thickness, the kidney reinforcing and miscarriage preventing pills, aspirin and estrogen play a synergistic treatment role, the postoperative re-adhesion rate is remarkably reduced through combined treatment, and the fertility prognosis of a patient is improved; and the molecular mechanism of a TGF-beta1 pathway and EMT is deeply researched, and by inhibiting excessive activation of the TGF-beta1 signaling pathway, reducing endometrial fibrosis, regulating an epithelial-mesenchymal transition (EMT) process and promoting regeneration of endometrial epithelial cells, endometrial repair is further promoted, multi-target treatment is realized, and the treatment effect is remarkable. A brand-new and efficient treatment scheme is provided for treatment of intrauterine adhesion, an individualized treatment scheme can be formulated according to the specific conditions of patients, the treatment accuracy and effectiveness are improved, and important clinical significance and application value are achieved.

The invention discloses application of compound resina draconis in preparation of a medicine for treating acute myocardial infarction. The compound resina draconis has the effects of resisting free radical oxidation and platelet aggregation, expanding coronary artery, inhibiting increase of myocardial enzymology CPK and LDH and reducing myocardial oxygen consumption, so that the myocardial infarction range is reduced, and myocardial ischemic ST segment elevation is improved; the compound is combined with aspirin for treating acute myocardial infarction, and the compound and aspirin have a synergistic effect, play a role in resisting platelet aggregation and inhibit synthesis of thromboxane A2, and show a good ischemic myocardial protection effect. Meanwhile, according to the technical scheme that the compound resina draconis is used independently or combined with aspirin, the application range of the medicine is widened, contribution is made for research and development of the medicine for relieving side effects caused by aspirin treatment, and the application prospect is good.

The invention provides a pharmaceutical composition. The pharmaceutical composition is prepared from aspirin, atorvastatin, valsartan, hydrochlorothiazide, folic acid substances and pharmaceutically acceptable auxiliary materials. The pharmaceutical composition provided by the invention has the advantages that the pharmaceutical composition provided by the invention has a multi-target synergistic prevention effect on vascular diseases, especially cerebral embolism, that is, the composition not only can reduce blood pressure, blood fat and blood homocysteine level, but also has an effect of preventing thrombosis, and reduces the risk of cerebral apoplexy. In addition, the form of the pharmaceutical composition is beneficial to improving the medication compliance of patients.

The invention relates to an aspirin modified hydroxy ketone photoinitiator and a preparation method thereof. According to the aspirin modified hydroxy ketone photoinitiator and the preparation method thereof, carboxyl-containing aspirin and a hydroxyl-containing photoinitiator Darocure2959 are used as raw materials, and the aspirin modified hydroxy ketone photoinitiator is prepared through esterification. Aspirin is introduced to Darocure2959 molecules, the molecular weight is high, the light absorption and photo-initiation activity of the Darocure2959 molecules is high, the migration rate and volatility are low, the thermal stability is high, the migration rate of residual photoinitiators is only 10.2% of the migration rate of Darocure2959, the photoinitiators and fragments of the photoinitiators can be effectively fixed in a curing film, and the curing effect is good. Meanwhile, the introduction of the aspirin group endows the initiator with the drug function, and the initiator is suitable for medical light-cured materials such as light-cured teeth, light-cured medical adhesives and light-cured medical instruments. The preparation method has the advantages of easily available raw materials, low cost and simple preparation process.

The invention belongs to the technical field of biological medicines, and particularly discloses application of aspirin in enhancing the curative effect of tumor infiltrating lymphocyte on treating liver cancer. The invention discloses application of aspirin in preparation of a medicine for enhancing the curative effect of tumor infiltrating lymphocyte on hepatocellular carcinoma. The invention discloses an application of aspirin in enhancing the curative effect of tumor infiltrating lymphocyte on treating liver cancer, the aspirin overcomes the problem of drug resistance of TIL therapy in HCC by adjusting the immune cell function in a tumor microenvironment, and the treatment effect is improved.

The invention belongs to the technical field of biological medicine, and relates to an anticoagulant, in particular to an anticoagulant for a high-precision animal blood cell analyzer and application of the anticoagulant in leukocyte classification. The anticoagulant comprises a buffer and anticoagulation matrix component and an active component, wherein in every 100 mL of the anticoagulant, the buffer and anticoagulation matrix component formula comprises 1.5 to 2 g of citrate, 0.3 to 0.5 g of citric acid and 0.15 to 0.20 g of EDTA-K2 (Ethylene Diamine Tetraacetic Acid), and the active components comprise 0.08 to 0.10 g of low molecular weight enzymolysis carboxymethyl chitosan, 1.0 to 1.2 g of hydroxypropyl-beta-cyclodextrin, 10 to 15 mg of dipyridamole and 8 to 10 mg of aspirin. The anticoagulant effectively inhibits platelet activation, prevents platelet aggregation and leukocyte morphological deformation, realizes accurate identification in leukocyte five-classification, has a classification accuracy rate of 98%, and is suitable for veterinary clinical hematology examination and animal epidemic disease monitoring.

The invention relates to an application of a halophenol compound 2, 4 ', 5'-trihydroxy-5, 2 '-dibromo benzophenone in preparation of an analgesic drug. Experiments prove that the compound has a definite analgesic effect, can significantly inhibit mouse writhing reaction induced by acetic acid and II-phase inflammatory pain induced by formalin, and prolongs the thermal stimulation tail retraction incubation period, and the effect is superior to that of aspirin. Furthermore, in a nitroglycerin-induced migraine rat model, the compound can effectively improve behavioral symptoms and brain tissue pathological damage and remarkably regulate key index levels of CGRP, PGE2, ET-1, IL-1beta, IL-6, TNF-alpha, 5-HT and the like in plasma, which shows that the compound can be applied to preparation of analgesic drugs, preparation of drugs for treating migraine, preparation of drugs for treating migraine and the like. The invention particularly has important application value in medicines for preventing and / or treating migraine.

The application relates to the technical field of aspirin pharmaceutical chemistry, in particular to an aspirin-sulfonamide hybrid, a preparation method and application thereof. The preparation method can synthesize a plurality of novel aspirin-sulfonamide hybrids by taking piperazine as a bridge, and by a three-step continuous method of "acyl chlorination, sulfonamidation and N-acylation" according to a "molecular hybridization principle". In the process, only one separation and purification is performed, and the preparation steps are simple. The aspirin-sulfonamide hybrid prepared by the method is most effective on human non-small cell lung cancer cells A549, and the activity is more than 33 times higher than that of a parent aspirin, and is similar to the activity of an anticancer drug irinotecan. The aspirin-sulfonamide hybrid 3k prepared by the method has a certain inhibitory effect on various cancer cells. The hybrid can induce human non-small cell lung cancer A549 cell apoptosis in a concentration-dependent manner, and can induce human non-small cell lung cancer A549 cell cycle arrest in the G0 / G1 phase, and inhibit cell growth.

The present disclosure provides compositions and methods for inducing protein-protein heterodimerization in the presence of salicylic acid or a synthetic derivative thereof, useful for modulating signal transduction, protein activation, and gene expression in response to chemical stimuli.

The invention relates to an anti-inflammatory plasma matrix as well as a preparation method and application thereof. The anti-inflammatory plasma matrix comprises a plasma matrix and aspirin chitosan nanoparticles, the preparation method of the anti-inflammatory plasma matrix comprises the step of pressing a mixture of the plasma matrix and the aspirin chitosan nanoparticles to obtain the anti-inflammatory plasma matrix. Leukocyte contained in the plasma matrix in the anti-inflammatory plasma matrix can play an antibacterial role, aspirin can be slowly released by the aspirin chitosan nano-particles, the function of regulating and controlling bone regenerative cycle in an inflammatory state is achieved, and a chitosan shell also has certain antibacterial and anti-inflammatory effects. The prepared anti-inflammatory plasma matrix can be applied to preparation of drugs for treating periodontitis and peri-implantitis.

The application belongs to the technical field of biological medicine, and relates to an anticoagulant and application thereof in white blood cell classification for high-precision animal blood cell analyzers. The anticoagulant comprises two parts of buffer and anticoagulant matrix components and active components. In the anticoagulant, the buffer and anticoagulant matrix component formula comprises 1.5-2 g of citrate, 0.3-0.5 g of citric acid and 0.15-0.20 g of EDTA-K2 per 100 mL of the anticoagulant, and the active component comprises 0.08-0.10 g of low-molecular enzymatic hydrolysis carboxymethyl chitosan, 1.0-1.2 g of hydroxypropyl-beta-cyclodextrin, 10-15 mg of dipyridamole and 8-10 mg of aspirin. The anticoagulant effectively inhibits platelet activation, prevents platelet aggregation and white blood cell morphological deformation, accurately identifies in white blood cell five classification, and has a classification accuracy as high as 98%, and is suitable for veterinary clinical hematology examination and animal disease monitoring.

The application belongs to the technical field of regenerative medicine, and particularly relates to an ASP / BFP-1 sustained-release nanofiber membrane and a preparation method and application thereof. In the initial stage of bone repair, matrix metalloproteinase-2 (MMP-2) secreted by a large number of stem cells can effectively degrade gelatin and polylysine in the nanofiber membrane coating, so as to sequentially release aspirin and bone formation peptide-1 in the drug-loaded coating. The released aspirin can control inflammation, and the bone formation peptide-1 can enhance the osteogenic potential of stem cells and guide bone tissue regeneration.

The application discloses a magnesium complex taking aspirin or an oxygen-deficiency promoting derivative thereof as a ligand, a preparation method and application thereof in preparation of a medicine for treating coronary heart disease. The structural formula of the magnesium complex is shown in the following formula I-IV: the magnesium carbonate is reacted with nitric acid to obtain magnesium nitrate; the aspirin is reacted with sodium bicarbonate to obtain a neutral sodium salt of aspirin; the neutral sodium salt of aspirin is reacted with the magnesium nitrate according to a molar ratio of 1:1 or 2:1 to obtain the magnesium complex shown in the formula I or II. The aspirin is reacted with p-nitrobenzyl alcohol to obtain an oxygen-deficiency promoting derivative of aspirin; the oxygen-deficiency promoting derivative of aspirin is reacted with the magnesium nitrate according to a molar ratio of 1:1 or 2:1 to prepare the magnesium complex shown in the formula III or IV. The application has a remarkable repairing effect on heart damage caused by myocardial ischemia and the like.

The invention relates to a vase solution for preserving cut lily flowers of an OT hybrid line and application of the vase solution. The vase solution takes water as a solvent and comprises salicylic acid, citric acid, calcium chloride, 6-benayl aminopurine, aspirin, ascorbic acid, silver thiosulfate and cane sugar. The vase solution can improve the ornamental quality of cut flowers, remarkably prolong the service life of flowering branches and delay turbidity of the vase solution; in addition, the soluble sugar content and peroxidase content of the petals can be increased, and the malondialdehyde content of the petals can be reduced. The vase solution provided by the invention has the advantages of low cost, and simple and easy preparation and use.

The invention provides an isoquinoline derivative with a novel structure, a pharmaceutically acceptable salt thereof, a preparation method of the isoquinoline derivative, a pharmaceutical composition containing the isoquinoline derivative and pharmaceutical application of the isoquinoline derivative, and belongs to the technical field of medicines. In-vitro experiments show that the isoquinoline derivative has significant inhibitory activity on arachidonic acid-induced platelet aggregation, and the antiplatelet activity of part of compounds is superior to that of aspirin. In a rat carotid artery thrombosis model induced by FeCl3, the isoquinoline derivative remarkably prolongs thrombosis time and reduces thrombus weight, and the in-vivo antithrombotic curative effect of the isoquinoline derivative is equivalent to that of aspirin and ticagrelor. A mouse tail bleeding model shows that the side effects of bleeding amount and bleeding time of the isoquinoline derivative are obviously lower than those of aspirin and ticagrelor. Therefore, the series of isoquinoline derivatives have the advantages of efficient antithrombotic effect and low bleeding risk, and have good application prospects in preparation of drugs for preventing and treating thrombotic diseases. In addition, the preparation method provided by the invention has the advantages of easily available raw materials, simple steps and strong operability, and the obtained target product has high quality and good efficiency.

The present application relates to the technical field of biological medicine, and more particularly to the application of aspirin in treating uterine fibroid degeneration during pregnancy. The application of aspirin in preparing a drug or health product for treating and / or preventing uterine fibroid degeneration during pregnancy. The dosage of aspirin in the drug is 100 mg per day. The present application uses aspirin to treat and / or prevent uterine fibroid degeneration during pregnancy, and the drug is widely used during pregnancy. It has been basically confirmed that the drug can be used for a long time in pregnant women, and the drug has the functions of relieving pain, improving blood flow, not being limited to gestational weeks, and being able to be used for a long time. The application of the drug can reduce the hospitalization rate of patients. For high-risk groups with pregnancy combined with uterine fibroid degeneration, the drug can be used as a preventive drug to reduce the occurrence of uterine fibroid degeneration. The treatment of the drug can significantly reduce the patients who change to surgical treatment due to the failure of conservative treatment of myoma degeneration.

This invention discloses the application of a drug in the prevention or treatment of hydrocephalus, belonging to the field of pharmaceutical formulation technology. The drug comprises a pharmaceutically acceptable formulation of one or more of the following active ingredients: compound A, compound B, or compound C, and their pharmaceutically acceptable salts, solvates, or crystal forms; compound A is carbaspirin calcium, compound B is aspirin, and compound C is salicylic acid. This invention utilizes the above-mentioned drug in the prevention or treatment of hydrocephalus. Carbaspirin calcium and its metabolites can significantly reduce ventricular enlargement in a hydrocephalus model rat, and carbaspirin calcium and its metabolites show promise in the preparation of drugs for treating hydrocephalus, providing an effective candidate drug to alleviate the suffering of hydrocephalus patients, reduce treatment risks and costs; it broadens the scope of action of carbaspirin calcium and optimizes the stability formulation of carbaspirin calcium.

The present application provides a kind of nereid polypeptide antithrombotic preparation, belong to the technical field of biopharmaceuticals.The present application finds that nereid plasmin polypeptide can inhibit the reaction of thrombin and fibrinogen to generate fibrin, thereby inhibiting the blood clotting reaction through in vitro test.Nereid plasmin polypeptide is determined for in vitro anti-platelet aggregation activity, and the inhibition rate of 640 μg / ml nereid plasmin polypeptide for anti-platelet aggregation is 75.68%, close to the inhibition effect of 1 mg / ml aspirin.The present application finds that nereid plasmin polypeptide group has the pharmacodynamic effect of reducing the weight of thrombus and the ratio of thrombus weight and length through nereid plasmin polypeptide antithrombotic effect test, has good antithrombotic effect, and can be used as nereid polypeptide antithrombotic preparation.

The application discloses a preparation method of self-assembled nanomedicine for improving fetal growth restriction and application thereof. Aspirin raw medicine, polyethyleneimine and phenyl borate are dissolved in dimethyl sulfoxide, and after being mixed uniformly, the mixture is placed into an ultrasonic cleaner until the medicine powder is completely dissolved, then the mixed solution is placed in a dialysis bag, and the organic solvent is removed by rotating dialysis in deionized water, finally, the solution in the dialysis bag is freeze-dried, and the self-assembled nanomedicine is obtained. The medicine is injected through a vein to improve the pathological pregnancy environment of hypoxia, oxidative stress and inflammation related to fetal growth restriction in a gestation period, and promote long-term growth and development of the development-restricted fetus. The self-assembling method is simple and easy to operate, low in price, and the organic solvent is easy to remove, and the stability is good and the immunogenicity is free. More importantly, under a treatment dose much higher than the treatment dose, the self-assembled nanomedicine has no toxicity to the mother and fetus, and the safety development of the fetus in the gestation period is ensured.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a preparation method of a forest musk deer excrement-derived anti-inflammatory and analgesic extract. The invention discloses an anti-inflammatory and / or analgesic product. The effective component of the product comprises a forest musk deer excrement extract. The anti-inflammatory and analgesic effects of the forest musk deer excrement extract are verified through experiments for the first time, the anti-inflammatory effect is equivalent to that of dexamethasone, and the analgesic effect is equivalent to that of aspirin. The forest musk deer excrement extract prepared by the invention is easy to prepare, has biological safety, is low in price and convenient to prepare and use, and has a wide application prospect and a good economic value.

The invention discloses an anti-tumor medicine composition with a synergistic effect and application of the anti-tumor medicine composition, the composition is composed of DHA and Aspirin, and the molar ratio of DHA to Aspirin is 1: 1000; the invention provides a different drug concentration ratio scheme for treating cancer cells, inhibiting proliferation and activation of cancer cells and inducing apoptosis of the cancer cells by combining medication under low drug concentration, and compared with a traditional scheme, the scheme weakens drug resistance of the cells, has a safer and more effective medication concentration ratio at a lower concentration, and can be used for treating the cancer cells and inhibiting the proliferation and activation of the cancer cells and inducing apoptosis of the cancer cells. The toxic reaction of an organism caused by high-concentration drugs is weakened.

1.The name of the design product: packaging box (alengling aspirin enteric-coated tablets). 2.The use of the design product: used for the outer packaging of medicines. 3.The design points of the design product: the combination of shape, pattern and color. 4.The picture or photo that best shows the design points: front view. 5.The design contains colors.

The application provides a trifunctional tetravalent platinum compound of captopril-aspirin ligand and a reference drug of a bifunctional tetravalent platinum compound of captopril; and develops a nanomedicine Tf-GEVs@Pt(IV) of the aspirin-captopril trifunctional tetravalent platinum compound loaded in grapefruit extracellular vesicles (GEVs). The Tf-GEVs@Pt(IV) is prepared from the trifunctional tetravalent platinum compound as an active ingredient, the carrier grapefruit extracellular vesicles (GEVs), the carrier DSPE-PEG and the transferrin modified targeting carrier DSPE-PEG-Tf. The Tf-GEVs@Pt(IV) can release the active component trifunctional tetravalent platinum compound in vivo. In addition to causing DNA damage, the trifunctional tetravalent platinum compound as the active component of the nanomedicine can effectively regulate inflammatory, fibrotic and immunosuppressive TME. The nanomedicine has a significant anti-tumor ability and has excellent therapeutic effect on metastatic malignant tumors, and is expected to provide a new candidate drug for clinical treatment of tumors and provide a new direction for research and development of new platinum drugs and anti-metastatic malignant tumor drugs.

A recombinant tumor-homing bacterium having constitutive prokaryotic expression cassettes comprising two or more homologous cancer associated antigens, each of the respective homologous cancer associated antigens associated with a transport signal from a distinct transport system, a regulating expression cassette encoding a regulator and an aspirin-inducible prokaryotic expression cassette encoding a set of immunomodulator fusion peptides operably linked to an inducible promoter, each of said immunomodulator fusion peptides comprising a heterologous immunomodulator associated with a secretion signal, said heterologous immunomodulator selected from a list consisting of: LIGHT, GMCSF, SIRP alpha, and IL18.

The invention relates to application of aspirin in preparation of an anti-schistosoma japonicum medicine, and in the invention, by applying a schistosoma japonicum infection mouse model, the treatment effect of aspirin on schistosoma japonicum is found. Specifically, the aspirin can significantly reduce the number of insect bodies infected in mice and the number of eggs deposited in livers, and can effectively inhibit the antigen secretion ability of the eggs infected in the livers of the mice, the granuloma inflammation induced by the eggs and the hepatic fibrosis degree, so that the aspirin can be applied to treatment of schistosoma japonicum katsurada. And a new application of aspirin is added clinically. As a non-steroidal anti-inflammatory drug, aspirin is widely applied clinically, has the advantages of safety, reliability, stability, low cost, easiness in obtaining and the like, and is relatively deep in pharmacological research and relatively clear in action mechanism. Therefore, the scheme of the invention is suitable for clinical popularization and use.

The invention relates to the technical field of environmental medicine and reproductive toxicology, in particular to application of aspirin in prevention and / or treatment of male reproductive injury caused by rare earth elements. The invention also relates to a method for improving sperm quality reduction caused by rare earth element exposure. The method comprises the step of administering an effective dose of aspirin or a pharmaceutically acceptable salt thereof to an individual in need thereof. The invention also relates to a pharmaceutical composition for preventing and / or treating male reproductive injury caused by rare earth elements. The cognitive limitation of a traditional oxidative stress mechanism is broken through, a new mechanism of rare earth reproductive toxicity is disclosed from a new perspective of testis immune microenvironment for the first time, and an intervention scheme aiming at the new mechanism is provided. According to the invention, the aspirin is creatively used for solving the novel public health problem of low-dose long-term exposure of rare earth elements for the first time, and a new application field is developed for non-steroidal anti-inflammatory drugs.

The invention discloses a medicament for improving tobacco quality and economic benefit and an application method, the medicament comprises one or more of a slicing medicament, a quality improving medicament, a disease preventing medicament and a nutrition medicament, the slicing medicament comprises NH4NO3, KNO3, NH4SO4, KH2PO4, VC, MgSO4, NAA and aspirin; the quality improving agent is prepared from FeSO4, H3BO3 and MnSO4; the disease prevention medicament is prepared from NH4NO3, KNO3, NH4SO4, KH2PO4, VC (Vitamin C), MgSO4, NAA (Naphthalene Acetic Acid) and aspirin; the nutrient agent is prepared from K2SO4, FeSO4, H3BO3 and MnSO4. Experimental results show that after the improved medicament formula is adopted, the yield, quality and flavor substances of the tobacco leaves are obviously improved, and the method has good practical value for further improving the economic value of the tobacco leaf planting industry. And on the other hand, the inventor further adjusts the bottle insertion type medicament bottle structure in the prior art, so that the bottle insertion type medicament bottle is more suitable for application of tobacco plants.